scholarly journals Prevention of neutropenia as an important factor in successful chemotherapy for head and neck cancer

2021 ◽  
Vol 11 (3) ◽  
pp. 72-82
Author(s):  
L. G. Babicheva ◽  
S. O. Podvyaznikov
Keyword(s):  
Risk Factors ◽  
Head And Neck Cancer ◽  
Febrile Neutropenia ◽  
Head And Neck ◽  
Treatment Efficacy ◽  
Infectious Complications ◽  
Colony Stimulating Factors ◽  
Neck Tumors ◽  
Potential Risks ◽  
Grade Iii

Despite the advances in supportive care for cancer patients, they often develop such a serious complication of chemotherapy as febrile neutropenia. This disorder is the main cause of reduced treatment efficacy because of the lower doses of cytostatics or even withdrawal of myelosuppressive therapy in some cases. The mortality rate from infectious complications of febrile neutropenia currently reaches 10 %.Presence of risk factors in combination with aggressive chemotherapy necessitates prevention of febrile neutropenia to reduce potential risks of complications. Synthetic granulocyte colony-stimulating factors can be used to address this issue.Among patients with head and neck tumors, the most vulnerable population includes individuals receiving TPF or DCF regimen or chemoradiotherapy. Such patients require preventive administration of granulocyte colony-stimulating factors. Patients with grade III–IV neutropenia require prevention of febrile neutropenia with pegylated forms of granulocyte colony-stimulating factors (such as empegfilgrastim). This will ensure optimal treatment outcomes.

The Risk Factors of Head and Neck Cancer and Their General Patterns in Australia: A Descriptive Review and Update

2014 ◽  
Vol 33 (1) ◽  
pp. 45-57 ◽  
Author(s):  
Jagtar Singh ◽  
Ramya Ramamoorthi ◽  
Siddhartha Baxi ◽  
Rama` Jayaraj ◽  
Mahiban Thomas
Keyword(s):  
Risk Factors ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer

scholarly journals Risk factors for radiation-induced dental caries in patients with head and neck cancer

2017 ◽  
Vol 2 (3) ◽  
Author(s):  
Sakiko Soutome ◽  
Madoka Funahara ◽  
Saki Hayashida ◽  
Kazutaka Nakamura ◽  
Masahiro Umeda
Keyword(s):  
Risk Factors ◽  
Head And Neck Cancer ◽  
Dental Caries ◽  
Head And Neck ◽  
Neck Cancer ◽  
Radiation Induced

Risk factors for surgical site infection in head and neck cancer

2021 ◽  
Author(s):  
Chengwen Gan ◽  
Yannan Wang ◽  
Yan Tang ◽  
Kai Wang ◽  
Bincan Sun ◽  
...  
Keyword(s):  
Risk Factors ◽  
Head And Neck Cancer ◽  
Surgical Site Infection ◽  
Head And Neck ◽  
Neck Cancer ◽  
Site Infection

scholarly journals Carbon ion reirradiation compared to intensity-modulated re-radiotherapy for recurrent head and neck cancer (CARE): a randomized controlled trial

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Thomas Held ◽  
Kristin Lang ◽  
Sebastian Regnery ◽  
Katharina Weusthof ◽  
Adriane Hommertgen ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Clinical Outcome ◽  
Head And Neck ◽  
Neck Cancer ◽  
Severe Toxicity ◽  
Carbon Ion ◽  
Intensity Modulated ◽  
Link Type ◽  
Recurrent Head ◽  
Grade Iii

Abstract Background Intensity-modulated re-radiotherapy (reIMRT) has been established as a standard local treatment option in patients with non-resectable, recurrent head and neck cancer (rHNC). However, the clinical outcome is unfavorable and severe toxicities (≥grade III) occurred in 30–40% of patients. The primary aim of the current trial is to investigate carbon ion reirradiation (reCIRT) compared to reIMRT in patients with rHNC regarding safety/toxicity as well as local control, overall survival (OS), and quality of life (QoL). Methods The present trial will be performed as a single center, two-armed, prospective phase II study. A maximum of 72 patients will be treated with either reIMRT or reCIRT to evaluate severe (≥grade III) treatment-related toxicities (randomization ratio 1:1). The primary target value is to generate less than 35% acute/subacute severe toxicity (≥grade III), according to the Common Terminology Criteria for Adverse Events v5.0, within 6 months after study treatment. The total dose of reirradiation will range between 51 and 60 Gy or Gy (RBE), depending primarily on the radiotherapy interval and the cumulative dose to organs at risk. Individual dose prescription will be at the discretion of the treating radiation oncologist. The local and distant progression-free survival 12 months after reirradiation, the OS, and the QoL are the secondary endpoints of the trial. Explorative trial objectives are the longitudinal investigation of clinical patient-related parameters, tumor parameters on radiological imaging, and blood-based tumor analytics. Discussion Recent retrospective studies suggested that reCIRT could represent a feasible and effective treatment modality for rHNC. This current randomized prospective trial is the first to investigate the toxicity and clinical outcome of reCIRT compared to reIMRT in patients with rHNC. Trial registration ClinicalTrials.gov; NCT04185974; December 4th 2019.

Sign in / Sign up

Export Citation Format

Share Document